Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ethan Rubinstein

Showing results (41-50 of 97) with videos related to

Pageof 10
Sort By:
Expert Review of Anti-Infective Therapy|January 31, 2006
Tigecycline: a novel glycylcycline antibioticGeorge G Zhanel, James A Karlowsky, Ethan Rubinstein, et al.
The Journal of Antimicrobial Chemotherapy|April 17, 2013
Integrating pharmacokinetics, pharmacodynamics and MIC distributions to assess changing antimicrobial activity against clinical isolates of Pseudomonas aeruginosa causing infections in Canadian hospitals (CANWARD)Sheryl A Zelenitsky, Ethan Rubinstein, Robert E Ariano, et al.
Critical Care Clinics|October 8, 2013
Infective endocarditis in the intensive care unitYoav Keynan, Rohit Singal, Kanwal Kumar, et al.
The Journal of Antimicrobial Chemotherapy|December 26, 2001
Once-daily versus twice-daily intravenous administration of vancomycin for infections in hospitalized patientsEytan Cohen, Alexander Dadashev, Moshe Drucker, et al.
Journal of Clinical Microbiology|November 28, 2007
In vitro bactericidal activity of Streptococcus pneumoniae and bactericidal susceptibility of Staphylococcus aureus strains isolated from cocolonized versus noncocolonized childrenGili Regev-Yochay, Richard Malley, Ethan Rubinstein, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 5, 2014
Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureusG Ralph Corey, Ethan Rubinstein, Martin E Stryjewski, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|March 1, 2002
Lower respiratory tract infections: etiology, current treatment, and experience with fluoroquinolonesEthan Rubinstein, Claude Carbon, Manickam Rangaraj, et al.
European Journal of Pediatrics|October 20, 2006
Comparison of community-acquired methicillin-resistant Staphylococcus aureus bacteremia to other staphylococcal species in a neonatal intensive care unitJacob Kuint, Asher Barzilai, Gili Regev-Yochay, et al.
BMC Infectious Diseases|April 9, 2014
Effect of vancomycin serum trough levels on outcomes in patients with nosocomial pneumonia due to Staphylococcus aureus: a retrospective, post hoc, subgroup analysis of the Phase 3 ATTAIN studiesSteven L Barriere, Martin E Stryjewski, G Ralph Corey, et al.
International Journal of Antimicrobial Agents|January 15, 2013
Vancomycin pharmacodynamics and survival in patients with methicillin-resistant Staphylococcus aureus-associated septic shockSheryl Zelenitsky, Ethan Rubinstein, Robert Ariano, et al.
Pageof 10

Showing results (41-50 of 97) with videos related to

Sort By:
Pageof 10
Expert Review of Anti-Infective Therapy|January 31, 2006
Tigecycline: a novel glycylcycline antibioticGeorge G Zhanel, James A Karlowsky, Ethan Rubinstein, et al.
The Journal of Antimicrobial Chemotherapy|April 17, 2013
Integrating pharmacokinetics, pharmacodynamics and MIC distributions to assess changing antimicrobial activity against clinical isolates of Pseudomonas aeruginosa causing infections in Canadian hospitals (CANWARD)Sheryl A Zelenitsky, Ethan Rubinstein, Robert E Ariano, et al.
Critical Care Clinics|October 8, 2013
Infective endocarditis in the intensive care unitYoav Keynan, Rohit Singal, Kanwal Kumar, et al.
The Journal of Antimicrobial Chemotherapy|December 26, 2001
Once-daily versus twice-daily intravenous administration of vancomycin for infections in hospitalized patientsEytan Cohen, Alexander Dadashev, Moshe Drucker, et al.
Journal of Clinical Microbiology|November 28, 2007
In vitro bactericidal activity of Streptococcus pneumoniae and bactericidal susceptibility of Staphylococcus aureus strains isolated from cocolonized versus noncocolonized childrenGili Regev-Yochay, Richard Malley, Ethan Rubinstein, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 5, 2014
Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureusG Ralph Corey, Ethan Rubinstein, Martin E Stryjewski, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|March 1, 2002
Lower respiratory tract infections: etiology, current treatment, and experience with fluoroquinolonesEthan Rubinstein, Claude Carbon, Manickam Rangaraj, et al.
European Journal of Pediatrics|October 20, 2006
Comparison of community-acquired methicillin-resistant Staphylococcus aureus bacteremia to other staphylococcal species in a neonatal intensive care unitJacob Kuint, Asher Barzilai, Gili Regev-Yochay, et al.
BMC Infectious Diseases|April 9, 2014
Effect of vancomycin serum trough levels on outcomes in patients with nosocomial pneumonia due to Staphylococcus aureus: a retrospective, post hoc, subgroup analysis of the Phase 3 ATTAIN studiesSteven L Barriere, Martin E Stryjewski, G Ralph Corey, et al.
International Journal of Antimicrobial Agents|January 15, 2013
Vancomycin pharmacodynamics and survival in patients with methicillin-resistant Staphylococcus aureus-associated septic shockSheryl Zelenitsky, Ethan Rubinstein, Robert Ariano, et al.
Pageof 10